𝐂𝐚𝐫𝐜𝐢𝐧𝐨𝐭𝐞𝐜𝐡, a health startup, has just raised a staggering £4.2m to turbocharge the development of its innovative 3D-printed micro-tumour technology.
Imagine a world where cancer treatments are not a one-size-fits-all, but tailored to each individual. That’s the world Carcinotech is striving to create. By crafting 3D-printed tumours from patients’ own biopsies and blood samples, they’re bringing personalised medicine to the forefront of cancer treatment.
This recent cash injection, led by Eos Advisory and other key investors, is set to catapult Carcinotech onto the global stage with a planned expansion to the US. It’s a thrilling chapter following their previous £1.6m funding round in 2022.
Carcinotech is not just changing the game; it’s rewriting the rules, offering a new hope in the battle against cancer. Stay tuned as they continue to break barriers and transform the future of cancer treatment.